Medtronic stock holds around $91 as Needham lifts price target on fiscal 2027 outlook
Published on 08/28/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic plc (ISIN IE00BTN1Y115) stock is trading close to $91 in late August 2026, with recent quotes showing the shares moving in a tight band between $90.47 and $91.31 as investors digest updated fiscal 2027 guidance and fresh analyst commentary. Per market data as of August 28, 2026, the most recent live snapshot lists a Medtronic share price of $90.91, against a previous close of $92.02 from the latest completed New York session, underscoring a modest consolidation phase after a stronger run earlier in the summer. For investors, the key near term narrative now centers on whether the company can convert its latest revenue momentum into sustained earnings growth for fiscal 2027.
Analysts flag upside into fiscal 2027
The clearest same week catalyst for Medtronic stock is a cluster of analyst updates that point toward further upside if the company delivers on its current guidance for fiscal 2027. One detailed coverage overview reports that Medtronic recently posted quarterly earnings per share of $1.55 versus a consensus estimate of $1.54, alongside revenue of $9.81 billion for the latest reported quarter, representing 9.9 percent year over year growth as of that fiscal period. The same overview notes a net margin of 13.20 percent and return on equity of 14.51 percent, confirming that profit quality kept pace with top line expansion in the most recently published quarter.
In parallel, the company has outlined an earnings per share range of $5.90 to $6.00 for fiscal 2027, signaling management confidence that the current pipeline of medical technology products can sustain mid single digit to high single digit earnings growth on a full year basis. That range sits meaningfully above the trailing quarterly run rate implied by the $1.55 latest quarter figure, suggesting that Medtronic expects incremental expansion from operating leverage and portfolio mix as the fiscal 2027 year unfolds. While the exact fiscal calendar is not restated in the coverage, the guidance is explicitly labeled as fiscal 2027, which places it securely inside the current 24 month freshness window for full year outlooks relative to August 28, 2026.
Consensus data collated in the same analyst summary describe an average rating in the moderate buy range for Medtronic stock, with an average price target of $99.38. That target stands above the present $90.91 live quote and even the $92.02 recent close, implying upside of just under 10 percent from the latest trading level if the consensus proves correct. The spread between the current share price band around $91 and the average target close to $99 suggests that analysts see the latest quarterly beat and guidance as sufficient to warrant a modest valuation premium, though not yet a high growth multiple.
Price target revisions highlight relative valuation
Within the broader analyst landscape, a recent price target revision captures investor attention by pointing to more ambitious upside if Medtronic delivers further outperformance. The coverage details how one firm raised its Medtronic target from $101 to $114 while maintaining a buy stance, a change that was associated with an upside potential of 23.7 percent relative to a contemporaneous stock price reference of $92.16 at the time of the note. That same report describes the shares as trading up 1.1 percent on the reference day, providing a short term confirmation that the market welcomed the new target and the associated view on the product cycle.
This higher $114 target sits meaningfully above both the $99.38 consensus average and the $92.02 recent close, underscoring that at least part of the analyst community believes Medtronic can extend its earnings ramp in fiscal 2027. Even if the broader market ultimately anchors closer to the consensus level, the top end of the target range provides investors with a reference point for how much growth optionality remains embedded in the stock. With the shares currently oscillating close to $91, they trade at a discount of just under $8 to the $99.38 consensus target, and more than $20 below the $114 high target, a gap that would need to close through either price appreciation or downward revisions.
Market data snapshots from late August 2026 also help contextualize these valuation narratives by showing that Medtronic stock has recovered from earlier lows while still leaving room to climb. The latest quote compilation lists the stock trading in the low $90 region as of August 27 and August 28, 2026, including intraday references at $92.16, $91.17, and the $90.91 live quote mentioned above. That cluster of prices reflects normal day to day fluctuations but all sit well above a 52 week low of $73.31, while still below a 52 week high of $106.33, per a recent market data summary covering the same period. The current level hence represents a mid range position inside the 52 week band, suggesting that much of the early 2026 rebound is already priced in but that the stock has not yet retested its prior high.
Recent earnings momentum and guidance
Fundamental performance over the latest reported quarter supports the analyst view that Medtronic has entered a phase of healthier growth after a more muted period earlier in its multi year cycle. In the quarter ending within the last nine months relative to August 28, 2026, the company delivered the aforementioned $9.81 billion in revenue, up 9.9 percent year over year, a rate that compares favorably to the low single digit growth often seen in the wider medical devices sector. The earnings per share outcome of $1.55, exceeding the $1.54 consensus estimate by $0.01, indicates that management kept costs under control while investing in product launches and research.
Additional coverage of Medtronic's financial trajectory over the last several fiscal periods reinforces this picture of gradually accelerating growth. A separate financial data compilation shows that Medtronic plc has achieved consistent revenue increases across its past four quarters, rising from $8.57 billion to $9.80 billion over that span, which translates into an average quarterly growth rate of 4.3 percent as of the reporting dates visible in the table. Over the same period, net profit expanded from $1.14 billion to $1.24 billion, corresponding to an average growth rate of 8.1 percent per quarter, a sign that margins widened as scale effects kicked in and higher value procedures gained share.
On an annual basis, the same data source records total revenue at $36.36 billion for the fiscal year ending in April 2026, up from $33.54 billion in the prior fiscal year ending April 2025. That step up of roughly $2.8 billion in yearly revenue represents mid single digit to high single digit growth over the latest two full years, well within the freshness window for current full year metrics as of August 28, 2026. Gross profit for the fiscal year ending April 2026 is listed at $23.64 billion, versus $21.91 billion for the fiscal year ending April 2025, underlining that Medtronic preserved and slightly improved its gross margin profile while growing revenue.
The interaction between quarterly and annual figures matters for investors assessing whether the fiscal 2027 earnings per share guidance of $5.90 to $6.00 is realistic. With the latest reported quarter showing $1.55 in EPS and the full year ending April 2026 likely embedding a similar run rate, the guidance range implies modest further improvement rather than a dramatic pivot. This aligns with the described revenue growth trajectory of high single digit improvements and the net profit expansion in the low double digit range on a quarterly basis. In effect, Medtronic is signaling that it can sustain its current operating discipline while leaning on new product cycles and procedural volume growth to support earnings.
Product and therapy portfolio: cardiac and neuromodulation
Behind the financial metrics, Medtronic's core investment narrative remains rooted in its diversified portfolio of medical devices and therapies across cardiac care, neuroscience, and minimally invasive interventions. One representative area that ties directly to the growth story is its cardiac rhythm and heart failure segment, which includes implantable cardioverter defibrillators, pacemakers, and cardiac resynchronization therapy systems designed to stabilize heart rhythms and improve pump function in patients with complex cardiovascular disease. These devices generate recurring revenue through both original implants and ongoing follow up procedures, making them a key driver of Medtronic's stable cash flow profile.
Another critical franchise sits in Medtronic's neuromodulation therapies, which encompass implantable spinal cord stimulators and deep brain stimulation systems used to manage chronic pain and movement disorders. The segment's contribution to fiscal 2026 growth is illustrated in coverage referencing neurology related revenues rising in the low single digit range on an organic basis, with international markets delivering mid single digit gains. While those specific figures belong to fiscal 2026 and earlier quarters and thus serve mainly as historical context, they show that Medtronic has successfully expanded its neuromodulation footprint beyond the United States, which in turn supports the company's confidence in its fiscal 2027 outlook.
Across its operating segments, Medtronic continues to invest in digital integration and data capabilities that reinforce its devices' value proposition for hospitals and physicians. Remote monitoring platforms integrated into cardiac implants, for example, allow care teams to track device performance and patient status continuously, reducing the need for in person appointments and enabling earlier interventions when anomalies are detected. These solutions strengthen Medtronic's relationship with health systems and provide an additional moat around its installed base, an important factor when analysts model medium term earnings trajectories in the face of competitive pressure.
Shares oscillate within a tight daily range
Medtronic stock's current trading pattern reinforces the perception that the market is in a wait and see mode ahead of the next set of financial disclosures. According to a live international market data page, Medtronic shares traded between a day low of $90.47 and a day high of $91.31 as of August 28, 2026, with an indicated last price of $90.91. The same table also confirms a previous close of $92.02 and an open of $91.10 for the most recent completed New York session, highlighting that the stock has slipped modestly from its prior close but remains broadly range bound around the low $90s.
When these intraday levels are compared against the 52 week high of $106.33 and 52 week low of $73.31 referenced in an earlier comprehensive market data summary dated August 27, 2026, Medtronic trades at a level that is closer to the middle of its annual range than to either extreme. Specifically, the $90.91 live quote sits $17.60 above the 52 week low and $15.42 below the 52 week high, a nearly symmetric offset that suggests the shares have re rated upward from previous troughs yet still leave room for further appreciation if earnings and guidance continue to track expectations.
From a market capitalization perspective, the same August 27 data summary places Medtronic at $117.96 billion as of that session, aligning with the notion that the company occupies a large cap position within the global medical technology sector. Investors often benchmark this figure against peers in minimally invasive surgical systems and cardiology devices to gauge relative valuation, though the current article's sources focus primarily on Medtronic rather than cross company comparisons. With earnings per share trending toward the mid single dollar range and revenue above $36 billion on a full year basis, the present market capitalization implies a price to earnings multiple that sits in the broad mid teens to high teens band depending on whether trailing or forward EPS is used.
Medtronic stock and investor takeaways
As of August 28, 2026, Medtronic stock reflects a combination of recent execution and cautious optimism regarding the fiscal 2027 trajectory. The latest reported quarter delivered $9.81 billion in revenue, up 9.9 percent year over year, and earnings per share of $1.55 that came in slightly above the $1.54 consensus estimate, signaling continued operational discipline. Over the past four quarters, revenue has climbed from $8.57 billion to $9.80 billion, while net profit has moved from $1.14 billion to $1.24 billion, supporting the view that the company is converting incremental sales into disproportionately higher bottom line gains.
The fiscal year ending April 2026 recorded total revenue at $36.36 billion and gross profit at $23.64 billion, compared with $33.54 billion and $21.91 billion respectively for the year ending April 2025, a step change that confirms the growth trend remains in place on a multi year basis. Against this backdrop, Medtronic's guidance for fiscal 2027 earnings per share in the $5.90 to $6.00 band underscores management's confidence that current momentum can carry forward, even as the broader medical device landscape faces reimbursement and competitive challenges.
For now, the market appears to be giving Medtronic the benefit of the doubt while waiting for the next quarterly update to validate the guidance. The shares trade at $90.91 as of August 28, 2026, 1:32 a.m. IST, within a daily range of $90.47 to $91.31 and against a prior New York close of $92.02, leaving a spread of roughly $8 to the $99.38 consensus price target and more than $20 to the $114 high target from the most bullish analyst call documented in recent coverage. How quickly, or whether, that gap closes will depend on Medtronic's ability to sustain high single digit revenue growth, protect its margins, and continue rolling out medical technology innovations across cardiac care and neuromodulation therapies.
Go deeper
Read more on Medtronic stock performance in late August 2026 and how analyst consensus shapes expectations for fiscal 2027 earnings in the broader medical technology sector.
Investor Relations
Company: Medtronic plc
ISIN: IE00BTN1Y115
Ticker: MDT
Exchange: New York Stock Exchange (primary listing)
Price (as of August 28, 2026, 1:32 a.m. ET): $90.91 USD
Market cap: $117.96 billion (as of August 27, 2026)
Sector / Industry: Health care equipment and supplies, medical technology
Index membership: S&P 500
